Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion

The Committee for Medicinal Products for Human Use rendered a positive opinion for Livmarli for the treatment of PFIC in patients aged three months and older in May. MIRM has also submitted an additional supplemental new drug application to the FDA seeking label expansion for a higher concentration formulation of Livmarli, which was used in the MARCH study to include treatment of younger patients with PFIC. Feedback from the regulatory body is expected later in 2024. Some better-ranked stocks in the healthc ...